Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston 77030-2399, USA.
H
H
Heslop
C
C
Rooney
M
M
Brenner
R
R
Krance
G
G
Carrum
B
B
Gahn
C
C
Bollard
S
S
Khan
A
A
Gee
U
U
Popat
M
M
Gresik
D
D
Przepiorka
I
I
Kuehnle
B
B
Grilley
D016026:Bone Marrow Transplantation / Q000379:methods*; D002460:Cell Line; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005240:Feasibility Studies; D005260:Female; D015316:Genetic Therapy; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000276:immunology; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D009355:Neomycin / Q000378:metabolism*; D012008:Recurrence; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism*
D009355:Neomycin